CoChat
Sign Up
Cited by 21

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation

Famta, Paras, Shah, Saurabh, Vambhurkar, Ganesh, Pandey, Giriraj, Bagasariya, Deepkumar, Kumar, Kondasingh Charan, Prasad, Sajja Bhanu, Shinde, Akshay, Wagh, Suraj, Srinivasarao, Dadi A., Kumar, Rahul, Khatri, Dharmendra Kumar, Asthana, Amit, Srivastava, Saurabh·2025·Drug Delivery and Translational Research
DOI 10.1007/s13346-024-01669-9
Open this paper in CoChat — free account

Abstract

Breast cancer (BC) is the most commonly diagnosed cancer among women. Chemo-, immune- and photothermal therapies are employed to manage BC. However, the tumor microenvironment (TME) prevents free drugs and nanocarriers (NCs) from entering the tumor premises. Formulation scientists rely on enhanced permeation and retention (EPR) to extravasate NCs in the TME. However, recent research has demonstrated the inconsistent nature of EPR among different patients and tumor types. In addition, angiogenesis, high intra-tumor fluid pressure, desmoplasia, and high cell and extracellular matrix density resist the accumulation of NCs in the TME. In this review, we discuss TME normalization as an approach to improve the penetration of drugs and NCSs in the tumor premises. Strategies such as normalization of tumor vessels, reversal of hypoxia, alleviation of high intra-tumor pressure, and infiltration of lymphocytes for the reversal of therapy failure have been discussed in this manuscript. Strategies to promote the infiltration of anticancer immune cells in the TME after vascular normalization have been discussed. Studies strategizing time points to administer TME-normalizing agents are highlighted. Mechanistic pathways controlling the angiogenesis and normalization processes are discussed along with the studies. This review will provide greater tumor-targeting insights to the formulation scientists.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13346-024-01669-9

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 158

  1. Famta P, Shah S, Jain N, Kumar KC, Bagasariya D, Khatri DK, et al. Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer. Life Sci. 2022;310:121125. · DOI
  2. Famta P, Shah S, Jain N, Srinivasarao DA, Murthy A, Ahmed T, et al. Albumin-hitchhiking: Fostering the pharmacokinetics and anticancer therapeutics. J Control Release. 2023;353:166–85. · DOI
  3. Famta P, Shah S, Jain N, Srinivasarao DA, Vambhurkar G, Shahrukh S, et al. Nanocarrier-based drug delivery via cell-hitchhiking: Emphasizing pharmacokinetic perspective towards taming the “big-old” tumors. J Drug Deliv Sci Technol. 2023;89:105050. · DOI
  4. Teleanu RI, Chircov C, Grumezescu AM, Teleanu DM. Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. J Clin Med. 2020;9:84. · DOI
  5. Ludwig N, Rubenich DS, Zaręba Ł, Siewiera J, Pieper J, Braganhol E, et al. Potential roles of tumor cell-and stroma cell-derived small extracellular vesicles in promoting a pro-angiogenic tumor microenvironment. Cancers (Basel). 2020;12:1–15. · DOI
  6. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745–70. · DOI
  7. Zeng A, Wang SR, He YX, Yan Y, Zhang Y. Progress in understanding of the stalk and tip cells formation involvement in angiogenesis mechanisms. Tissue Cell. 2021;73:101626. · DOI
  8. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs - PubMed [Internet]. [cited 2024 Jun 25]. Available from: https://pubmed.ncbi.nlm.nih.gov/2946403/
  9. Schito L. Hypoxia-dependent angiogenesis and lymphangiogenesis in cancer. Adv Exp Med Biol. 2019;1136:71–85. · DOI
  10. Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019;25:5449–57. · DOI
  11. Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cell Oncol. 2021;44:715–37. · DOI
  12. Yehya AHS, Asif M, Petersen SH, Subramaniam AV, Kono K, Majid AMSA, et al. Angiogenesis: Managing the culprits behind tumorigenesis and metastasis. Medicina (Lithuania). 2018;54:8.
  13. Jena MK, Janjanam J. Role of extracellular matrix in breast cancer development: A brief update. F1000Res. 2018;7. · DOI
  14. Zuazo-Gaztelu I, Casanovas O. Unraveling the role of angiogenesis in cancer ecosystems. Front Oncol. 2018;8:248. · DOI
  15. Folkman J, Kalluri R. Beginning of angiogenesis research. In: Kufe DW, Pollock RE, Weichselbaum RR et al. editors. H-FCMedicine 6th edition. H (ON): BD. Beginning of angiogenesis research. Available from: https://www.ncbi.nlm.nih.gov/books/NBK13877/. 2003;1–31.
  16. Hillen F, Griffioen AW. Tumour vascularization: Sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007;26:489–502. · DOI
  17. Saravanan S, Vimalraj S, Pavani K, Nikarika R, Sumantran VN. Intussusceptive angiogenesis as a key therapeutic target for cancer therapy. Life Sci. 2020;252:117670. · DOI
  18. Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo Y, et al. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol Cancer. 2021;20:1–18. · DOI
  19. Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020;39:1–19. · DOI
  20. Shen Y, Quan J, Wang M, Li S, Yang J, Lv M, et al. Tumor vasculogenic mimicry formation as an unfavorable prognostic indicator in patients with breast cancer. Oncotarget. 2017;8:56408–16. · DOI
  21. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res. 2007;100:782–94. · DOI
  22. Dallinga MG, Boas SE, Klaassen I, Merks RH, van Noorden CJ, Schlingemann RO. Tip Cells in Angiogenesis. eLS. 2015;1–10. · DOI
  23. Huang CC, Kuo HM, Wu PC, Cheng SH, Chang TT, Chang YC, et al. Soluble delta-like 1 homolog (DLK1) stimulates angiogenesis through Notch1/Akt/eNOS signaling in endothelial cells. Angiogenesis. 2018;21:299–312. · DOI
  24. Hida K, Maishi N, Annan DA, Hida Y. Contribution of tumor endothelial cells in cancer progression. Int J Mol Sci. 2018;19:1272. · DOI
  25. Akil A, Gutiérrez-García AK, Guenter R, Rose JB, Beck AW, Chen H, et al. Notch Signaling in Vascular Endothelial Cells, Angiogenesis, and Tumor Progression: An Update and Prospective. Front Cell Dev Biol. 2021;9:177. · DOI
  26. Lin J, Lin Y, Su L, Su Q, Guo W, Huang X, et al. The role of Jagged1/Notch pathway-mediated angiogenesis of hepatocarcinoma cells in vitro, and the effects of the spleen-invigorating and blood stasis-removing recipe. Oncol Lett. 2017;14:3616–22. · DOI
  27. Fong GH, Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ. 2008;15:635–41. · DOI
  28. Zhu Z, Hou Q, Guo H. NT5DC2 knockdown inhibits colorectal carcinoma progression by repressing metastasis, angiogenesis and tumor-associated macrophage recruitment: A mechanism involving VEGF signaling. Exp Cell Res. 2020;397: 112311. · DOI
  29. Mezu-Ndubuisi OJ, Maheshwari A. The role of integrins in inflammation and angiogenesis. Pediatr Res. 2021;89:1619–26. · DOI
  30. Xu S, Zhang H, Chong Y, Guan B, Guo P. YAP Promotes VEGFA Expression and Tumor Angiogenesis Though Gli2 in Human Renal Cell Carcinoma. Arch Med Res. 2019;50:225–33. · DOI
  31. Zhu Q, Li J, Wu Q, Cheng Y, Zheng H, Zhan T, et al. Linc-OIP5 in the breast cancer cells regulates angiogenesis of human umbilical vein endothelial cells through YAP1/Notch/NRP1 signaling circuit at a tumor microenvironment. Biol Res. 2020;53:1–12. · DOI
  32. Yeldag G, Rice A, Hernández A del R. Chemoresistance and the self-maintaining tumor microenvironment. Cancers (Basel). 2018;10. · DOI
  33. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–54. · DOI · Paper page
  34. Rasouli SS, Jolma IW, Friis HA. Impact of spatially varying hydraulic conductivities on tumor interstitial fluid pressure distribution. Inform Med Unlocked. 2019;16:100175. · DOI
  35. Garnier L, Gkountidi AO, Hugues S. Tumor-associated lymphatic vessel features and immunomodulatory functions. Front Immunol. 2019;10. · DOI
  36. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular network architecture in a mammary carcinoma. EXS. 1992;61:74–80.
  37. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc Res. 1990;40:246–63. · DOI
  38. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989;37:77–104. · DOI
  39. Raavé R, van Kuppevelt TH, Daamen WF. Chemotherapeutic drug delivery by tumoral extracellular matrix targeting. J Control Release. 2018;274:1–8. · DOI · Paper page
  40. Purkayastha P, Jaiswal MK, Lele TP. Molecular cancer cell responses to solid compressive stress and interstitial fluid pressure. Cytoskeleton. 2021;78:312–22. · DOI
  41. Secomb TW, Hsu R, Dewhirst MW, Klitzman B, Gross JF. Analysis of oxygen transport to tumor tissue by microvascular networks. Int J Radiat Oncol Biol Phys. 1993;25:481–9. · DOI
  42. Ishihara S, Haga H. Matrix Stiffness Contributes to Cancer Progression by Regulating Transcription Factors. Cancers (Basel). 2022;14:1049. · DOI
  43. Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. JNCCN Journal of the National Comprehensive Cancer Network. 2020;18:479–89. · DOI
  44. Deshmukh SK, Srivastava SK, Poosarla T, Dyess DL, Holliday NP, Singh AP, et al. Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy. Ann Transl Med. 2019;7:593–593. · DOI
  45. Abaza A, Sid Idris F, Anis Shaikh H, Vahora I, Moparthi KP, Al Rushaidi MT, et al. Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics. Cureus. 2023 · DOI · Paper page
  46. Ghahremani Dehbokri S, Alizadeh N, Isazadeh A, Baghbanzadeh A, Abbaspour-Ravasjani S, Hajiasgharzadeh K, et al. CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer. Curr Mol Med. 2023;23:521–6. · DOI
  47. Swoboda A, Nanda R. Immune Checkpoint Blockade for Breast Cancer. 2018. p. 155–65. · DOI
  48. Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9:7. · DOI
  49. Alhawary SIS, Saleh EAM, Mamajanov NA, S. Gilmanova N, Alsaab HO, Alghamdi A, et al. Breast cancer vaccines A comprehensive and updated review. Pathol Res Pract. 2023;249:154735. · DOI
  50. Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–86. · DOI
  51. Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, et al. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res. 2021;9:1–16. · DOI
  52. Meng S, Li LI, Zhou M, Jiang W, Heng NIU, Yang K. Distribution and prognostic value of tumor-infiltrating T cells in breast cancer. Mol Med Rep. 2018;18:4247–58.
  53. Vito A, El-Sayes N, Mossman K. Hypoxia-Driven Immune Escape in the Tumor Microenvironment. Cells. 2020;9. · DOI
  54. Lee CT, MacE T, Repasky EA. Hypoxia-driven immunosuppression: A new reason to use thermal therapy in the treatment of cancer? Int J Hyperth. 2010;26:232–46. · DOI
  55. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607–15. · DOI
  56. Harjunpää H, Asens ML, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078. · DOI
  57. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001;108:15–23. · DOI
  58. Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med. 1994;180:2365–70. · DOI
  59. Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer. 2003;3:807–20. · DOI
  60. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117–29. · DOI · Paper page
  61. Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-β. Breast Cancer Res. 2000;2:125. · DOI
  62. Mouri H, Sakaguchi K, Sawayama T, Senoh T, Ohta T, Nishimura M, et al. Suppressive effects of transforming growth factor-beta1 produced by hepatocellular carcinoma cell lines on interferon-gamma production by peripheral blood mononuclear cells. Acta Med Okayama. 2002;56:309–15.
  63. Zhang S, Regan K, Najera J, Grinstaff MW, Datta M, Nia HT. The peritumor microenvironment: physics and immunity. Trends Cancer. 2023;9:609–23. · DOI
  64. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, et al. RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo. Cancer Res. 2004;64:7596–603. · DOI
  65. Lee J-C, Lee K-M, Kim D-W, Heo DS. Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients. J Immunol. 2004;172:7335–40. · DOI
  66. Chitadze G, Kabelitz D. Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell‐based therapeutic approaches. Scand J Immunol. 2022;96. · DOI
  67. Beck C, Schreiber H, Rowley DA. Role of TGF-? in immune-evasion of cancer. Microsc Res Tech. 2001;52:387–95. · DOI
  68. Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Investig. 2013;123:3925–40. · DOI
  69. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. 2003;63:2150–7.
  70. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol. 1999;163:5020–8. · DOI
  71. Bhat AA, Goyal A, Thapa R, almalki WH, Kazmi I, Alzarea SI, et al. Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer. Cytokine. 2023;171:156376. · DOI
  72. Wang Y, Xiang Y, Xin VW, Wang X-W, Peng X-C, Liu X-Q, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13:107. · DOI
  73. Vitiello PF, Shainheit MG, Allison EM, Adler EP, Kurt RA. Impact of tumor-derived CCL2 on T cell effector function. Immunol Lett. 2004;91:239–45. · DOI
  74. Peng L, Shu S, Krauss JC. Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. Cancer Res. 1997;57:4849–54.
  75. Pozzi S, Satchi-Fainaro R. The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine. Adv Drug Deliv Rev. 2024;209: 115318. · DOI
  76. Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer. 2004;40:1934–40. · DOI
  77. Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001;2:907–16. · DOI · Paper page
  78. Thomsen LL, Miles DW. Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev. 1998;17:107–18. · DOI
  79. Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799–820. · DOI · Paper page
  80. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996;26:1308–13. · DOI
  81. Takahashi A, Kono K, Ichihara F, Sugai H, Amemiya H, Iizuka H, et al. Macrophages in tumor-draining lymph node with different characteristics induce T-cell apoptosis in patients with advanced stage-gastric cancer. Int J Cancer. 2003;104:393–9. · DOI
  82. He M, Wang M, Xu T, Zhang M, Dai H, Wang C, et al. Reactive oxygen species-powered cancer immunotherapy: Current status and challenges. J Control Release. 2023;356:623–48. · DOI
  83. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 1979;2005(307):58–62.
  84. Cantelmo AR, Pircher A, Kalucka J, Carmeliet P. Vessel pruning or healing: endothelial metabolism as a novel target? Expert Opin Ther Targets. 2017;21:239–47. · DOI
  85. Abou Khouzam R, Brodaczewska K, Filipiak A, Zeinelabdin NA, Buart S, Szczylik C, et al. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. Front Immunol. 2021;11:3479. · DOI
  86. Thews O, Riemann A. Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer Metastasis Rev. 2019;38:113–29. · DOI
  87. Li S, Zhang Q, Hong Y. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy. Technol Cancer Res Treat. 2020;19. · DOI
  88. Huynh H, Lee LY, Goh KY, Ong R, Hao HX, Huang A, et al. Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology. 2019;69:943–58. · DOI
  89. Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409–26. · DOI
  90. Magnussen AL, Mills IG. Vascular normalisation as the stepping stone into tumour microenvironment transformation. Br J Cancer. 2021;125:324–36. · DOI · Paper page
  91. Shi R, Liao C, Zhang Q. Hypoxia-driven effects in cancer: Characterization, mechanisms, and therapeutic implications. Cells. 2021;10:1–26. · DOI
  92. Li W, Quan YY, Li Y, Lu L, Cui M. Monitoring of tumor vascular normalization: The key points from basic research to clinical application. Cancer Manag Res. 2018;10:4163–72. · DOI
  93. Yu M, Han Y, Zhuo H, Zhang S. Endostar, a Modified Endostatin Induces Vascular Normalization to Improve Chemotherapy Efficacy Through Suppression of Src Signaling Pathway. Cancer Biother Radiopharm. 2018;33:131–8.
  94. Abyaneh HS, Regenold M, McKee TD, Allen C, Gauthier MA. Towards extracellular matrix normalization for improved treatment of solid tumors. Theranostics. 2020;10:1960–80. · DOI
  95. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–65. · DOI
  96. Cong L, Maishi N, Annan DA, Young MF, Morimoto H, Morimoto M, et al. Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy. Breast Cancer Res. 2021;23:1–17. · DOI
  97. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: Reassessing the target. Cancer Res. 2012;72:1909–14. · DOI
  98. Drevs J. VEGF and angiogenesis: implications for breast cancer therapy. Eur J Cancer Suppl. 2008;6:7–13. · DOI
  99. Sun Z, Lan X, Xu S, Li S, Xi Y. Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: A network meta-analysis. BMC Cancer. 2020;20:1–17. · DOI
  100. Goldfarb SB, Dickler MN. Bevacizumab in metastatic breast cancer: When may it be used? Ther Adv Med Oncol. 2011;3:85–93. · DOI
  101. Li Q, Yan H, Zhao P, Yang Y, Cao B. Efficacy and safety of bevacizumab combined with chemotherapy for managing metastatic breast cancer: A meta-analysis of randomized controlled trials. Sci Rep. 2015;5:1–11.
  102. Boucher Y, Kumar AS, Posada JM, Gjini E, Pfaff K, Lipschitz M, et al. Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. NPJ Precis Oncol. 2021;5:1–6. · DOI
  103. Yadav K, Lim J, Choo J, Ow SGW, Wong A, Lee M, et al. Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer. Breast Cancer Res Treat. 2022;192:131–42. · DOI
  104. Mollard S, Ciccolini J, Imbs DC, El Cheikh R, Barbolosi D, Benzekry S. Model driven optimization of antiangiogenics + cytotoxics combination: Application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis. Oncotarget. 2017;8:23087–98. · DOI
  105. Bin Chen B, Lu YS, Lin CH, Chen WW, Wu PF, Hsu CY, et al. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer. 2016;16:1–8. · DOI
  106. Salmon RM, Guo J, Wood JH, Tong Z, Beech JS, Lawera A, et al. Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms. Nat Commun. 2020;11:1–16. · DOI
  107. Ayuso-Íñigo B, Méndez-García L, Pericacho M, Muñoz-Félix JM. The dual effect of the BMP9–ALK1 pathway in blood vessels: An opportunity for cancer therapy improvement? Cancers (Basel). 2021;13:5412. · DOI
  108. Ouarné M, Bouvard C, Boneva G, Mallet C, Ribeiro J, Desroches-Castan A, et al. BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer. J Exp Clin Cancer Res. 2018;37:1–12. · DOI
  109. Chen Q, Xu L, Chen J, Yang Z, Liang C, Yang Y, et al. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy. Biomaterials. 2017;148:69–80. · DOI · Paper page
  110. Mirando AC, Patil A, Rafie CI, Christmas BJ, Pandey NB, Stearns V, et al. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 2020;9:1760685. · DOI
  111. Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade. Clin Cancer Res. 2020;26:1712–24. · DOI
  112. Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, et al. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. Int J Mol Sci. 2023;24:3226. · DOI
  113. Kim SJ, Jung KH, Son MK, Park JH, Yan HH, Fang Z, et al. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery. Cancer Lett. 2017;403:339–53. · DOI
  114. Kunduzova O, Alet N, Delesque-Touchard N, Millet L, Castan-Laurell I, Muller C, et al. Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes. FASEB J. 2008;22:4146–53. · DOI
  115. Claesson-Welsh L. What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality. EMBO Mol Med. 2019;11:e10892. · DOI
  116. Uribesalgo I, Hoffmann D, Zhang Y, Kavirayani A, Lazovic J, Berta J, et al. Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. EMBO Mol Med. 2019;11:e9266. · DOI
  117. Jones LW, Viglianti BL, Tashjian JA, Kothadia SM, Keir ST, Freedland SJ, et al. Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer. J Appl Physiol. 2010;108:343–8. · DOI
  118. Schadler KL, Thomas NJ, Galie PA, Bhang DH, Roby KC, Addai P, et al. Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. Oncotarget. 2016;7:65429–40. · DOI · Paper page
  119. Broders-Bondon F, Nguyen Ho-Bouldoires TH, Fernandez-Sanchez M-E, Farge E. Mechanotransduction in tumor progression: The dark side of the force. J Cell Biol. 2018;217:1571–87. · DOI · Paper page
  120. Martin JD, Panagi M, Wang C, Khan TT, Martin MR, Voutouri C, et al. Dexamethasone Increases Cisplatin-Loaded Nanocarrier Delivery and Efficacy in Metastatic Breast Cancer by Normalizing the Tumor Microenvironment. ACS Nano. 2019. · DOI
  121. Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, et al. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics. 2020;10:1910–22. · DOI
  122. Mpekris F, Panagi M, Voutouri C, Martin JD, Samuel R, Takahashi S, et al. Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis. Advanced Science. 2021;8:2001917. · DOI
  123. Sorace AG, Quarles CC, Whisenant JG, Hanker AB, McIntyre JO, Sanchez VM, et al. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results. Breast Cancer Res Treat. 2016;155:273–84. · DOI
  124. Jain RK. Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell. 2014;26:605–22. · DOI · Paper page
  125. Ho YJ, Chu SW, Liao EC, Fan CH, Chan HL, Wei KC, et al. Normalization of tumor vasculature by oxygen microbubbles with ultrasound. Theranostics. 2019;9:7370–83. · DOI
  126. Wang Q, Xiang Q, Yu L, Hu T, Chen Y, Wang J, et al. Corrigendum: Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS (Front. Oncol, (2020), 9, (1545), Front Oncol. 2021;11:1545. · DOI
  127. Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL. Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol. 2018;200:432–42. · DOI
  128. Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer – considerations for patient prognosis. Cell Mol Immunol. 2020;17:570–5. · DOI
  129. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35:571–80. · DOI
  130. Pimenta EM, Barnes BJ. Role of tertiary lymphoid structures (TLS) in anti-tumor immunity: Potential tumor-induced cytokines/chemokines that regulate TLS formation in epithelial-derived cancers. Cancers (Basel). 2014;6:969–97. · DOI
  131. Thompson ED, Enriquez HL, Fu YX, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med. 2010;207:1791–804. · DOI
  132. Johansson-Percival A, He B, Li ZJ, Kjellén A, Russell K, Li J, et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat Immunol. 2017;18:1207–17. · DOI
  133. Pantelidou C, Jadhav H, Kothari A, Liu R, Guerriero JL, Shapiro GI. STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer. bioRxiv. 2021;2021.01.26.428337. · DOI
  134. Rivera Vargas T, Benoit-Lizon I, Apetoh L. Rationale for stimulator of interferon genes–targeted cancer immunotherapy. Eur J Cancer. 2017;75:86–97. · DOI
  135. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015;11:1018–30. · DOI · Paper page
  136. Yang H, Lee WS, Kong SJ, Kim CG, Kim JH, Chang SK, et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Investig. 2019;129:4350–64. · DOI
  137. Tarik Alhamdany A, Saeed AMH, Alaayedi M. Nanoemulsion and Solid Nanoemulsion for Improving Oral Delivery of a Breast Cancer Drug: Formulation, Evaluation, and a Comparison Study. Saudi Pharmaceutical Journal. 2021;29:1278–88. · DOI
  138. Kumari M, Sharma N, Manchanda R, Gupta N, Syed A, Bahkali AH, et al. PGMD/curcumin nanoparticles for the treatment of breast cancer. Sci Rep. 2021;11:3824. · DOI
  139. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002;4:95. · DOI
  140. Chaudhuri A, Ramesh K, Kumar DN, Dehari D, Singh S, Kumar D, et al. Polymeric micelles: A novel drug delivery system for the treatment of breast cancer. J Drug Deliv Sci Technol. 2022;77: 103886. · DOI
  141. Zenze M, Daniels A, Singh M. Dendrimers as Modifiers of Inorganic Nanoparticles for Therapeutic Delivery in Cancer. Pharmaceutics. 2023;15:398. · DOI
  142. Shah A, Aftab S, Nisar J, Ashiq MN, Iftikhar FJ. Nanocarriers for targeted drug delivery. J Drug Deliv Sci Technol. 2021;62: 102426. · DOI · Paper page
  143. Edis Z, Wang J, Waqas MK, Ijaz M, Ijaz M. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. Int J Nanomedicine. 2021;16:1313–30. · DOI
  144. Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS. Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems. Polymers (Basel). 2023;15:1596. · DOI
  145. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. Journal of Nanobiotechnology 2018 16:1 [Internet]. 2018 [cited 2024 Jun 25];16:1–33. Available from: https://jnanobiotechnology.biomedcentral.com/articles/https://doi.org/10.1186/s12951-018-0392-8 · DOI
  146. Siddique S, Chow JCL. Recent Advances in Functionalized Nanoparticles in Cancer Theranostics. Nanomaterials. 2022;12:2826. · DOI
  147. Luiz MT, Dutra JAP, De Araújo JTC, Di Filippo LD, Duarte JL, Chorilli M. Functionalization of Nanosystems in Cancer Treatment. Cancer Nanotechnol. Cham: Springer International Publishing; 2023. p. 71–101.
  148. Haripriyaa M, Suthindhiran K. Pharmacokinetics of nanoparticles: current knowledge, future directions and its implications in drug delivery. Futur J Pharm Sci. 2023;9:113. · DOI
  149. Dos Santos AF, De Almeida DRQ, Terra LF, Baptista MS, Labriola L. Photodynamic therapy in cancer treatment - an update review. J Cancer Metastasis Treat. 2019;2019:25. · DOI
  150. Shen Z, Ma Q, Zhou X, Zhang G, Hao G, Sun Y, et al. Strategies to improve photodynamic therapy efficacy by relieving the tumor hypoxia environment. NPG Asia Mater. 2021;13:1–19. · DOI
  151. Xu XL, Chen MX, Lou XF, Du YY, Shu GF, Qi J, et al. Sialic acid-modified mesoporous polydopamine induces tumor vessel normalization to enhance photodynamic therapy by inhibiting VE-cadherin internalization. Chem Eng J. 2021;414:128743. · DOI
  152. Li Y, Liu Y, Du B, Cheng G. Reshaping Tumor Blood Vessels to Enhance Drug Penetration with a Multistrategy Synergistic Nanosystem. Mol Pharm. 2020;17:3151–64. · DOI
  153. Wang L, Fang D, Xu J, Luo R. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020;20:1–10. · DOI
  154. Ishtiaq S, Edwards S, Sankaralingam A, Evans BAJ, Elford C, Frost ML, et al. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. Cytokine. 2015;71:154–60. · DOI
  155. Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activity. Cancer Res. 2005;65:4971–4. · DOI
  156. Jun Cai X, Dong Fei W, Ying XuY, Xu H, Yi Yang G, Wei Cao J, et al. Liposome-Encapsulated Zoledronate Favors Tumor Vascular Normalization and Enhances Anticancer Efficacy of Cisplatin. AAPS PharmSciTech. 2020;21:1–14. · DOI
  157. Teng RJ, Rana U, Afolayan AJ, Zhao B, Miao QR, Konduri GG. Nogo-B receptor modulates angiogenesis response of pulmonary artery endothelial cells through eNOS coupling. Am J Respir Cell Mol Biol. 2014;51:169–77. · DOI
  158. Wang B, Ding Y, Zhao X, Han X, Yang N, Zhang Y, et al. Delivery of small interfering RNA against Nogo-B receptor via tumor-acidity responsive nanoparticles for tumor vessel normalization and metastasis suppression. Biomaterials. 2018;175:110–22. · DOI

Cited by

Sorted by citations

See all 21

Metadata

Authors
Famta, P., Shah, S., Vambhurkar, G., Pandey, G., Bagasariya, D., Kumar, K. C., Prasad, S. B., Shinde, A., Wagh, S., Srinivasarao, D. A., Kumar, R., Khatri, D. K., Asthana, A., & Srivastava, S.
Venue
Drug Delivery and Translational Research
Publisher
Springer Science and Business Media LLC
Published
2024-07-15
Volume
15
Issue
2
Pages
389-406
ISSN
  • 2190-393X
  • 2190-3948
DOI
10.1007/s13346-024-01669-9
Cited by
21
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review